On Wednesday, I told you about my friend Pete, who passed on recommending Apple Inc. (NASDAQ: AAPL) to his Wall Street clients decades ago.
This was back in 1997, around the time the late Steve Jobs returned to run the Silicon Valley legend. Since then, the stock has gone from a split-adjusted $0.78 a share to $312, where it trades today. That kind of gain could turn $10,000 into more than $3.8 million.
Today, I have another anecdote to share with you. This one involves a friend I'll call "Steve."
In the summer of 2012, Steve told me over lunch he had recently sold all his Apple stock. He said he did so because he felt the new CEO, Tim Cook, would never match the innovation that occurred under Jobs.
Unfortunately, both of my friends missed the boat on Apple – and left a lot of money on the table.
I know Steve wasn't alone in thinking the Apple magic was over. It's smart to consider what could happen when a company gets a new leader – especially when the one being replaced was widely regarded as a "visionary genius," and when the stock had been so good to shareholders. Investors and media both questioned what Apple would become under Cook.
Apple has continued its historic run, rising as much as 395.6% in a little more than eight years. And it keeps reaching new levels, hitting its most recent closing high just last week.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.